Data on the clinical spectrum and therapeutic management of non-infectious mixed cryoglobulinemia vasculitis (CryoVas) in the era of hepatitis C virus screening are lacking.
Introduction
Cryoglobulinemia is defined as the presence of circulating immunoglobulins that precipitate with cold temperature and dissolve with rewarming, and is sorted according to the classification by Brouet et al. 1 . Type I cryoglobulins are associated with lymphoproliferative disorders, while MC (type II and III) are associated with connective tissue diseases, lymphoproliferative disorders, and chronic infections. When MC is found in the absence of well-defined disease, the syndrome is designated as "essential MC". Since the discovery of hepatitis C virus (HCV) infection in 1989, it has become clear that HCV is associated with most cases of MC. Among patients with MC, 60% to 90% are infected with HCV [2] [3] [4] [5] .
Cryoglobulinemia may be responsible for a systemic vasculitis (CryoVas), with manifestations ranging from MC syndrome (purpura, arthralgia, and asthenia) to more serious lesions with skin, neurologic and renal involvement 6 . In patients with HCV infection, the combination of PEGylated interferon-α with ribavirin is the current standard of care for patients with mild to moderate disease activity, whereas more aggressive treatment is needed in patients presenting with severe disease 7, 8 .
Data on the presentation, the efficacy and the safety of treatments in non-infectious mixed CryoVas in the era of HCV screening are lacking. The management of non-infectious
CryoVas has yet to be defined, although it is traditionally based on a combination of corticosteroids and immunosuppressants or plasmapheresis. The efficacy of these treatments is often disappointing 9 . More recently, limited data on the efficacy and safety of rituximab in non-infectious CryoVas have emerged, suggesting its interest in such patients 10 .
A survey was initiated in France in 2010 in order to better define the clinical spectrum and the efficacy and safety of treatments of non-infectious mixed CryoVas. Data from the 242 cases of CryoVas included in this survey are reported here.
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Methods

Patients
This retrospective survey was conducted in French university and general hospitals in the departments of internal medicine, hematology, nephrology, neurology, dermatology and rheumatology. The study was performed in accordance with the ethical standards of the Helsinki Declaration, and it was approved by the Pitié-Salpétrière Hospital institutional review board. The inclusion criteria for the study were: 1) type II or type III MC after detection and immunochemical typing; 2) systemic vasculitis; 3) diagnosis of CryoVas between January, 1995 and July, 2010. The exclusion criteria were the presence of anti-HCV and anti-human immunodeficiency virus (HIV) antibodies and hepatitis B surface antigen.
Although few studies suggested the existence of "occult" HCV and hepatitis B virus infection 11, 12 , the demonstration of HCV-RNA and HBV-DNA in ultracentrifuged serum, peripheral blood mononuclear cell samples or liver biopsy specimens were not available. A review performed in 2009 by Welker and Zeuzem 13 confirmed our data 14 and those of two other studies using sensitive assays and liver/PBMC assessment, reinforcing the absence of evidence of occult HCV infection.
Patients were considered to have systemic vasculitis if they had, in association with clinical manifestations of vasculitis (purpura, cutaneous ulcers or necrosis, arthralgia or arthritis, myalgia, peripheral neuropathy, renal involvement, cerebral vasculitis, gastrointestinal involvement), the following: 1) histologically-proven vasculitis (n=174); and/or 2) detectable cryoglobulinemia with at least purpura or cutaneous ulcers as a clinical manifestation in the absence of histology (n=68). Patients without histologically-proven vasculitis but with purpura or cutaneous ulcers and detectable MC were considered to have small-vessel vasculitis based on previously defined clinical and biological criteria 6, 15 . Twelve patients with non-typed cryoglobulinemia were considered to have MC in the absence of a serum patients with non-infectious mixed CryoVas from 81 centers were included (Figure 1 ).
Clinical and biological data were recorded for each patient at the time of the initial evaluation, during follow-up and at the end of follow-up, by the practitioners in charge of the patients using a standardized form. Laboratory assessment included the determination of the serum C3 and C4 fraction of complement, cryoglobulin level, serum creatinine level, and a urinalysis to screen for hematuria and a 24-hour urine protein exam. The diagnosis of B-cell non-Hodgkin lymphoma (B-NHL) was made on the basis of evidence of bone marrow, nodal, or extranodal lymphoproliferative disease with pathological features that were compatible with the World Health Organization's classification of neoplastic diseases 16 . Treatment characteristics were also recorded.
Response to therapy
The clinical response of vasculitis was defined by analyzing the course of the following main We next evaluated the efficacy and safety of treatments after adjusting for on confounding factors. Associations between prognostic factors and clinical response, serious infections and death were tested using Cox time-dependent modeling. We also compared the efficacy and safety of different therapeutic regimen i.e. corticosteroids alone versus combination therapy using corticosteroids plus immunosuppressive agents (alkylating agents or rituximab). In order to estimate the effect of treatment in the presence of time-dependent confounders [18] [19] [20] and in a situation where treatment is varying through follow-up, we used Cox marginal structural models (Cox-MSM). We created a pseudo population using the inverse probability of treatment weighting (IPTW), a method that calculates for each individual, at any observed time, weights from the probability of individuals receiving the treatment they actually received conditional on their observed covariates [19] [20] [21] . The baseline covariates included in the stabilized weights were: age, gender, GFR, and cause of CryoVas. As time-dependent variables were included in the model, vasculitis manifestations were gathered at each visit and before new treatment initiation. Several assumptions are however needed for the application of Cox-MSM. Differences were considered significant when P values were less than 0.05.
Results
Patient characteristics
The characteristics of the 242 patients with non-infectious CryoVas are shown in Table 1 .
The mean age at diagnosis was 62.6 ± 14.5 years, and 163 patients (69%) were female. 
Follow-up of patients
After a median follow-up of 54 months (interquartile range 9-77) corresponding to 1028 patients-years (py), severe infections were noted in 55 patients (23%, 5. 
Impact of therapeutic regimen on response to treatment and outcome
The data on 209 patients (86%) who received therapy (at least corticosteroids) and had an evaluable response to treatment were analyzed for outcome, i.e. efficacy and tolerance of treatments, severe infections and death. Treatments used in these patients during follow-up were: corticosteroids in all patients, alkylating agents in 92 patients, rituximab in 85 patients, plasmapheresis in 43 patients, and azathioprine or mycophenolate mofetil in 31 patients.
Patients received 1.8±1.2 lines of treatments, totalising 373 treatment periods. The treatments and the median dosage of corticosteroids used in the patients according to the cause of CryoVas, and the treatment efficacy and safety for the different therapeutic regimen i.e. corticosteroids alone, alkylating agents plus corticosteroids, rituximab plus corticosteroids, and the combination of rituximab plus alkylating agents and corticosteroids, are reported in Response rates to corticosteroids alone in refractory and/or relapsing patients were 33%, 59% and 45%, respectively. First-line use of alkylating agents plus corticosteroids provided a complete clinical response and renal and immunological responses in 62%, 86% and 73% of patients, respectively. Response rates in refractory and/or relapsing patients were 39%, 66% and 48%, respectively. First-line use of rituximab plus corticosteroids provided a complete clinical response and renal and immunological responses in 64%, 85% and 77% of patients, respectively. Response rates in refractory and/or relapsing patients were 66%, 88% and 84%, respectively. Refractory response rates were higher using corticosteroids alone, while rates of severe infections were higher using rituximab plus corticosteroids. The efficacy of rituximab plus corticosteroids was similar when used in first and second-line therapy. Alkylating agents plus corticosteroids and corticosteroids alone showed lower response rates when used as second-line therapy compared to first-line. The combination of rituximab plus alkylating agents and corticosteroids seems to provide a high efficacy, but the safety was poor with a high rate of severe infections (42%).
We next evaluated the efficacy and safety of treatments after adjusting for on and S2. The combination of rituximab plus corticosteroids was more effective than corticosteroids alone in achieving a complete clinical response (HR 3.7, P=0.01) (Figure 2) , a decrease in prednisone dosage to < 10 mg/day at month 6 (HR 2.5, P<0.0001) (Figure 3) , a Rituximab plus corticosteroids was associated with severe infections more frequently than corticosteroids alone (HR 9.0, P<0.0001), while the death rate did not differ between these two therapeutic regimen (HR 1.7, P=0.40). In patients who received rituximab, those with severe infection received high dose of corticosteroids more frequently than those without severe infection (dose > 50 mg/day in 71% of patients with infection vs. 39% in those without infection, P=0.008). In contrast, alkylating agents plus corticosteroids regimen was associated with severe infections less frequently than corticosteroids alone (HR 0.2, P=0.002), while the death rate did not differ between therapies (HR 0.6, P=0.50).
Discussion
Before the discovery of HCV in 1989, mixed cryoglobulinemia vasculitis was considered an essential or idiopathic disease in most cases. The systematic HCV screening performed in these patients revealed that most of the patients with mixed CryoVas are positive for HCV infection markers [2] [3] [4] [5] . Along this line, most of the previous data on the presentation, prognosis and therapeutic management of mixed CryoVas, derived from old studies including HCV-positive and negative patients, should thus be interpreted with caution and revisited according to HCV status. In the last decade, it has been clearly demonstrated that the therapeutic management and prognosis of HCV-related vasculitis differed from that of HCV-negative patients 4, [22] [23] [24] . To better define the clinical spectrum and the therapeutic management of non-infectious mixed CryoVas, we analyzed the data from 242 patients included in the French multicenter and transdisciplinary CryoVas survey, which constitutes the largest series reported so far in the literature.
This study describes the spectrum of clinical presentation and etiologic factors of noninfectious mixed CryoVas. Regarding demographics, both the mean age at the time of diagnosis and the sex ratio (predominance of females) were in keeping with what had been previously reported in large series of HCV-positive patients 24 and small series of HCVnegative patients 4, 5 . Rates for cutaneous, articular and renal involvement in the present study were comparable with those found in HCV-positive patients, while peripheral neuropathy seemed to be more frequent in the latter compared to non-infectious mixed CryoVas (74 vs.
52%) 24 . Our survey confirms that connective tissue diseases, and in particular primary
Sjögren's syndrome, hematologic disorders and essential mixed CryoVas remain the main causes of non-infectious mixed CryoVas, with a slightly higher rate of essential mixed However, rates of severe infections were higher using rituximab plus corticosteroids. We next decided to analyze the impact of treatments after adjustment for the time-dependent confounders using Cox-marginal structural models, which had been previously used in observational studies [18] [19] [20] . Although Cox-MSM cannot include all time-dependant rituximab showing a clinical and immunological response in more than 80%. Besides this dramatic efficacy, the occurrence of severe infections with similar rates compared to our survey was described. These infections occurred in a particular subset of patients, characterized by older age, renal failure (GFR < 60 mL/min) and the use of high dose corticosteroids. Overall, these findings suggest that rituximab plus corticosteroids could be the first therapeutic option in patients with severe non-infectious mixed cryoglobulinemia
vasculitis, but that corticosteroids should be rapidly tapered in order to decrease the risk of severe infection. The role of rituximab as first-line treatment in non-severe patients remains to be determined. 
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